Szabo, Peter M.
Vajdi, Amir
Kumar, Namit
Tolstorukov, Michael Y.
Chen, Benjamin J.
Edwards, Robin
Ligon, Keith L.
Chasalow, Scott D.
Chow, Kin-Hoe
Shetty, Aniket
Bolisetty, Mohan
Holloway, James L.
Golhar, Ryan
Kidd, Brian A.
Hull, Philip Ansumana
Houser, Jeff
Vlach, Logan
Siemers, Nathan O.
Saha, Saurabh
Article History
Received: 5 April 2022
Accepted: 19 January 2023
First Online: 21 February 2023
Competing interests
: P.M.S. is an employee of Fate Therapeutics. A.V., M.Y.T., K.-H.C., and A.S. have nothing to disclose. N.K., B.J.C., S.D.C., M.B., J.L.H., R.G., B.A.K., P.A.H., and J.H. are employees of and own stock in Bristol Myers Squibb. R.E. is a previous employee of Bristol Myers Squibb and owns stock in the company; and is an employee of Daiichi Sankyo, Inc. and owns stock in the company. K.L.L. has received financial support payable to Dana Farber Cancer Institute related to the submitted work. Outside the submitted work, K.L.L. has received personal fees from IntegraGen, RareCyte, and Bristol Myers Squibb and grants from Amgen, Lilly, and Bristol Myers Squibb. K.L.L. is also a cofounder of and owns equity in Travera LLC. L.V. is an employee of Vanderbilt University. N.O.S. is an employee of and owns stock in Abiosciences, Inc. S.S. is the CEO and Board Director of Centessa Pharmaceuticals.